Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has a cash flow conversion efficiency ratio of 0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€18.75 Million ≈ $21.91 Million USD) by net assets (€253.42 Million ≈ $296.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EUZ market cap overview for the company's overall valuation and market capitalisation.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their cash flow conversion efficiency. Explore EUZ cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Janux Therapeutics Inc
NASDAQ:JANX
|
-0.013x |
|
Beijing Qianjing Landscape Co
SHG:603778
|
0.347x |
|
VNDIRECT Securities Corp
VN:VND
|
-0.037x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Elevra Lithium Limited
AU:ELV
|
-0.051x |
|
PixArt Imaging
TWO:3227
|
0.032x |
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
N/A |
|
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A
SHE:300767
|
0.032x |
Annual Cash Flow Conversion Efficiency for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
The table below shows the annual cash flow conversion efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. View Eckert & Ziegler Strahlen- und Medizinte (EUZ) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €253.42 Million ≈ $296.28 Million |
€58.41 Million ≈ $68.28 Million |
0.230x | -22.03% |
| 2024-12-31 | €225.21 Million ≈ $263.30 Million |
€66.57 Million ≈ $77.83 Million |
0.296x | +39.76% |
| 2023-12-31 | €224.09 Million ≈ $261.99 Million |
€47.40 Million ≈ $55.41 Million |
0.212x | +31.74% |
| 2022-12-31 | €213.63 Million ≈ $249.75 Million |
€34.30 Million ≈ $40.10 Million |
0.161x | -8.70% |
| 2021-12-31 | €192.53 Million ≈ $225.08 Million |
€33.85 Million ≈ $39.58 Million |
0.176x | -25.07% |
| 2020-12-31 | €148.92 Million ≈ $174.10 Million |
€34.95 Million ≈ $40.86 Million |
0.235x | -19.06% |
| 2019-12-31 | €139.44 Million ≈ $163.02 Million |
€40.43 Million ≈ $47.27 Million |
0.290x | +69.34% |
| 2018-12-31 | €123.88 Million ≈ $144.83 Million |
€21.21 Million ≈ $24.80 Million |
0.171x | -25.00% |
| 2017-12-31 | €117.52 Million ≈ $137.39 Million |
€26.83 Million ≈ $31.36 Million |
0.228x | +26.71% |
| 2016-12-31 | €110.08 Million ≈ $128.69 Million |
€19.83 Million ≈ $23.19 Million |
0.180x | +16.19% |
| 2015-12-31 | €104.67 Million ≈ $122.37 Million |
€16.23 Million ≈ $18.97 Million |
0.155x | +37.54% |
| 2014-12-31 | €94.49 Million ≈ $110.47 Million |
€10.65 Million ≈ $12.45 Million |
0.113x | -30.65% |
| 2013-12-31 | €90.27 Million ≈ $105.53 Million |
€14.68 Million ≈ $17.16 Million |
0.163x | -- |
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more